Johnson & Johnson researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company operates through its Innovative Medicine and MedTech segments following the spinoff of its consumer health division.
Johnson & Johnson operates in the Healthcare sector and is a constituent of the S&P 500 index. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for JNJ.
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). JNJ Stock Intelligence Report. [stoxpulse.com/stocks/jnj]
Disclaimer: The information on this page about Johnson & Johnson (JNJ) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Johnson & Johnson.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
Earnings beat by 1%
Jun 30
Schmid bought 11K shares
3d ago
Schmid sold 11K shares
3d ago
How Much Upside Can BSX Stock's Growth Deliver?
11h ago
Was JNJ Stock Rally Actually Its Own?
13h ago
StoxPulse AI results for JNJ: Pulse Score 55/100. Primary sentiment trends from 15 news sources and 20 SEC filings indicate a bullish outlook.
Market Cap
$0
P/E Ratio
18.8
EPS
$2.10
Volume
3.9M
Avg Volume
—
Open
$268.04
Prev. Close
$268.04
Day Range
$274.75 - $277.80
50-Day Avg
—
200-Day Avg
—
52W High
$281.07
52W Low
$173.33
Sep 25
+0.5%
Dec 25
-0.1%
Mar 26
+0.3%
Jun 26
+0.9%
Beat estimates 3 of 4 quarters (75%)
Johnson & Johnson researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company operates through its Innovative Medicine and MedTech segments following the spinoff of its consumer health division.
How Much Upside Can BSX Stock's Growth Deliver?
Was JNJ Stock Rally Actually Its Own?
Johnson & Johnson Is Boring Which Makes Its Dividend Nearly Perfect.
Trailing rivals, AbbVie scores win with dual-acting myeloma drug
Timothy Schmid Exercises Options, Realizes $4.39M
Is Johnson & Johnson (JNJ) Cheap After The Louisiana Talc Verdict?
Protolabs CEO sees big impact from US reshoring despite potential tariffs
Is Merck Stock Pricing In A Post-Keytruda Future Too Soon?